Astrazeneca (AZN) Work In Process (2015 - 2025)

Astrazeneca (AZN) has reported Work In Process for 11 consecutive years, with $2.8 billion the latest figure, recorded in Q4 2025.

• In Q4 2025, Work In Process rose 21.69% year-over-year to $2.8 billion; the TTM figure through Dec 2025 stood at $2.8 billion (up 21.69% YoY), while the FY2025 annual figure was $2.8 billion, up 21.69% from the prior year.
• Work In Process came in at $2.8 billion for Q4 2025 at Astrazeneca, up from $2.3 billion in the prior quarter.
• The five-year high for Work In Process was $5.2 billion in Q4 2021, with the low at $1.9 billion in Q4 2022.
• Average Work In Process over 5 years is $2.9 billion, with a median of $2.3 billion recorded in 2023.
• Across the five-year window, Work In Process jumped 291.89% in 2021 and sank 64.26% in 2022, its largest moves.
• Year by year, Work In Process stood at $5.2 billion in 2021, then tumbled by 64.26% to $1.9 billion in 2022, then advanced by 24.73% to $2.3 billion in 2023, then decreased by 1.85% to $2.3 billion in 2024, then increased by 21.69% to $2.8 billion in 2025.
• According to Business Quant data, Work In Process over the past three periods registered $2.8 billion, $2.3 billion, and $2.3 billion for Q4 2025, Q4 2024, and Q4 2023 respectively.